Aminoglycosides Market Size & Share 2025 – 2034

Aminoglycosides Market Size

The global aminoglycosides market size was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 4% from 2025 to 2034. The broad-spectrum activity of aminoglycosides against Gram-negative bacteria, aminoglycosides are often prescribed to treat a multitude of bacterial infections, which include, but are not limited to, urinary tract infections, pneumonia, and sepsis, thus leading to an increased market demand.

Defense mechanisms adopted by bacteria from the aminoglycosides class continue to remain effective through gentamicin and tobramycin, so their usage remains prominent at hospitals, allowing market growth for the intravenous and topical formulations of the aminoglycosides.

Moreover, the offering of essential antibiotics by various governments, either through a subsidized system or a national healthcare program, is boosting the growth of the market by encouraging the use of aminoglycosides to treat a variety of infectious diseases. Applying formulation inhalation for the intravenous administration also serves as a primary factor for treating bronchial diseases, strengthening the market for the aminoglycosides.
 

Finally, technical advances made for medical equipment used in drug delivery facilitate increased efficiency for the medical application of these drugs. For example, initiatives by entities such as WHO and GAVI (Global Alliance for Vaccines and Immunization) augment the provision of antibiotics in low-resource targets, hence improving the usage of the same. As a result, the growing use of aminoglycosides in veterinary practice, along with affordable pricing and readiness of drugs, spurred the market growth.
 

Aminoglycosides are a group of antibiotics that are primarily used for the treatment of infections caused by aerobic gram-negative bacilli, but they have a wide scope covering many other microbes such as Staphylococci and Mycobacterium tuberculosis. It is presumed that aminoglycosides act by blocking protein production inside the bacterial cell.
 

Aminoglycosides Market Trends

The market is expected to grow due to these innovations and an increase in targeted drug formulations in aminoglycosides, such as those that aim to minimize nephrotoxicity, a side effect that is known to be encountered.
 

• Research data reveals that 10-20% of patients on aminoglycosides such as Gentamicin and Tobramycin present renal toxicity.
   
• Therefore, the ongoing sustained efforts to address these side effects with the new formulations coupled with constant research are igniting competition in the market.
   
• Moreover, the EU, US, and Brazil have approved other new drugs based on the medicament, and this has increased the range of drugs available in the market and consequently the growth of the market.
   

Aminoglycosides Market Analysis

Based on product, the global market is divided into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and other products. The gentamicin segment dominated the market and was valued at USD 541.6 million in 2024.
 

• The increase in bacterial diseases, which tend to be multi-drug resistant, has increased the requirement for potent drugs such as gentamicin. For instance, antimicrobial resistance (AMR) is becoming a global health problem. AMR could cause 10 million deaths per year by 2050, according to estimates made by the WHO.
   
• Moreover, with the growing concern that microbial infections will soon be entirely resistant to traditional antibiotics, healthcare practitioners are beginning to utilize a medication called gentamicin more frequently.
   
• The number of surgical procedures has increased along with the number of infections acquired while in the hospital, which means gentamicin, used in conjunction with other medications to help prevent further infection during surgery, is in higher demand, which in turn helps further increase the demand for gentamicin.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the application, the aminoglycosides market is categorized into bacterial infection, tuberculosis and other applications. The bacterial infection segment accounted for the highest market share of 65.5% in 2024. The segment is further bifurcated into respiratory infections, skin and soft tissue infection, bone infections, and urinary tract infections.
 

• The increasing number of infections acquired from hospitals or HAIs remain a growing problem, particularly pneumonia acquired from the use of ventilators, urinary infections, and bloodstream infections, all of which are associated with Gram-negative bacteria, mainly Pseudomonas aeruginosa and Klebsiella pneumoniae.
   
• Thus, considering the relevance of aminoglycosides in HAIs treatment, it is reported that about 20% of the ICU patients have infections that require the use of aminoglycosides, which additionally aids in the growth of the market.
   
• Furthermore, as the population of elderly continues to rise, they have a greater risk of getting infections due to the weakened immune system. This shift in demographics has caused an enhancement in the demand for effective antibacterial treatment, thereby increasing the prevalence of aminoglycoside antibiotics, which in turn aids in the overall expansion of the market.
   

Based on the route of administration, the aminoglycosides market is categorized into injectable, oral, topical and ophthalmic. The oral segment dominated the market in 2024 and is growing with a CAGR of 4.1% during the analysis period.
 

• Considering that the oral route is a non-invasive technique, it is much easier for the patients to take the medicine than if it was administered through injections or intravenous (IV) means of administration.
   
• Compared to parenteral formulations, the oral type of aminoglycosides is cheaper to both produce and dispense.
   
• Furthermore, the oral type lowers the need for IV setups, hospital visits, and professional dispensing, thus reducing healthcare expenses.
   
• Thus, more than 50 million people are estimated to be infected with amebiasis, which in turn fuels the market for oral aminoglycosides like paromomycin.
   
• Oral formulations are especially beneficial for gastrointestinal (GI) infections because they minimize systemic absorption and instead target the intestinal tract.
   

Based on end use, the aminoglycosides market is categorized into hospitals and clinics, research and academic institutes, homecare settings, and other end users. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 1.2 billion by 2034.

• Aminoglycosides are considered important in the treatment of hospital-acquired infections, which include severe cases such as pneumonia, sepsis, urinary tract infections, and meningitis, as they possess broad antibacterial action against Gram-negative strains.
   
• On the other hand, aminoglycosides are routinely given to patients undergoing orthopedic, cardiovascular, and gastrointestinal surgeries to minimize sepsis caused due to ECMO, TAH, and liver transplant.
   
• Aminoglycoside prescriptions are likely to rise as the construction of new hospitals and expansion of clinics in developing countries continues to grow.
   

In 2024, the U.S. held a significant position in the North America aminoglycosides market and was valued at USD 726.7 million.
 

• The growing incidence of bacterial infections is expected to enhance the growth of the market in the U.S. CDC estimates that over 2.8 million antimicrobial-resistant infections occur every year, resulting in over 35,000 deaths in the U.S.
   
• This has bolstered the requirement for strong antibiotics such as aminoglycosides, which serve to augment market expansion.
   
• Major factors include an increase in healthcare efficiency brought about by new diagnostic measures that help combat intense bacterial infections, thereby facilitating selective use of aminoglycosides.
   

Germany shows robust growth potential in the aminoglycosides market.
 

• Some such factors include well-developed healthcare systems, expanded research centers, and increasing government expenditures on healthcare to aid the growth in the market.
   
• Furthermore, like many of the developed nations, Germany suffers from a high prevalence rate of bacterial infections. These comprise nosocomial infections (NIs) and diseases caused by infections due to chronic conditions.
   
• In an also such measure, Germany actively supports antimicrobial resistance (AMR) through awareness building and education. For example, the German Ministry of Health claims that educational activities and the norms on proper antibiotic use are effective in reducing the incidence of resistant bacteria, which enable the aminoglycosides, which further facilitate the market development.
   

The aminoglycosides market in Asia Pacific is estimated to grow at a CAGR of 4.3% over the next few years.
 

• The rising number of infections and surgeries requiring hospital admission drive the increased use of aminoglycoside drugs, especially in a critical care condition.
   
• Also, the National Health Commission of China observes a growth in the rate of hospital admissions over the years, and this growth is evident across the ICUs where aminoglycoside drugs are dominantly used.
   
• In addition, the Chinese government has made major healthcare and medical research investments to enhance the national supply of advanced antibiotics like aminoglycosides.
   
• Furthermore, due to a large elderly populace in China who have a frail immune system and suffer from infections, there is a rise in demand for antibiotics such as aminoglycosides.
   

Brazil's aminoglycosides market is projected to witness growth in coming years.

• The fast-growing healthcare systems made by the government and private investors; Brazil seems to experience a higher growth in the market.
   
• Also, the Brazil government supports public revolution programs that are geared toward controlling infectious health conditions among the vulnerable. This has increased the use of antibiotics in both the public and private fields.
   

Saudi Arabia is anticipated to grow in the Middle East and African aminoglycosides market.
 

• The healthcare sector in Saudi Arabia has been investing in rapid growth initiated by Vision 2030. Additionally, there has been a rapid rise in chronic diseases such as diabetes, kidney diseases, and cancer, which raises the probability of bacterial infections, hence increasing the use of antibiotics like aminoglycosides.
   
• Furthermore, there is a range of Saudi norms that are in place encouraging a rational use of antibiotics like prescription drug accessibility.
   

Aminoglycosides Market Share

Some global pharmaceutical and biotechnological companies in amalgamation with regional companies take part in the competition of the market. Established pharmaceutical countries have wide awareness of aminoglycosides in a variety of brands. Emerging market generic producers continue to engage in fierce competition with their cost-effective substitutes. The companies are also engaging in research and development on innovative formulations which cater to addressing the antimicrobial resistance issue. Collaborative partnerships with the healthcare sector and regulatory bodies increase penetration into these markets.
 

Aminoglycosides Market Companies

Few of the prominent players operating in the aminoglycosides industry include:

• Aurobindo Pharma
• Bausch Health Companies
• Cipla
• Fresenius Kabi
• Kremoint Pharma (Bliss GVS Pharma)
• Meiji Seika Pharma (Meiji Holdings)
• Novartis
• Perrigo Company
• Pfizer
• Sun Pharmaceutical Industries
• Sanofi
• Teva Pharmaceuticals 
   

USPs for top market players:

• Comprehensive portfolio of key companies such as Novartis, Cipla, and Sun Pharmaceutical with easy affordability of generic formulation has made aminoglycosides accessible.
   
• Pfizer and Sanofi with their strong research and development activities are expected to develop next-generation amino-glycosides with improved efficacy and reduced toxicity.
   
• Global reach of Sanofi and Pfizer with trusted brand recognition among leading pharmaceutical companies and strong distribution networks is also contributing to their revenue growth.
   

Aminoglycosides Industry News

• In February 2024, Cipla Limited received approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India. Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. Plazomicin’ s introduction in India underscores Cipla's proactive response to the urgent global challenge of antimicrobial resistance (AMR).
   

The aminoglycosides market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Other products

Market, By Application

• Bacterial infection
  • Respiratory infections
  • Skin and soft tissue infections
  • Bone infections
  • Urinary tract infections (UTIs)
• Tuberculosis
• Other applications

Market, By Route of Administration

• Injectable
• Oral
• Topical
• Ophthalmic

Market, By End Use

• Hospitals and clinics
• Research and academic institutes
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE